Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

The European Regulatory Environment of RNA-Based Vaccines.

Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, Huber C, Khleif S, Kreiter S, Rammensee HG, Sahin U, Singh-Jasuja H, Türeci Ö, Kalinke U.

Methods Mol Biol. 2017;1499:203-222. Review.

PMID:
27987152
2.

[Tumor vaccines and peptide-loaded dendritic cells (DCs)].

Schummer V, Flindt S, Hinz T.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Nov;58(11-12):1254-8. doi: 10.1007/s00103-015-2242-2. Review. German.

PMID:
26349562
3.

The regulatory landscape for actively personalized cancer immunotherapies.

Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen KJ, Khleif SN, Kreiter S, Nielsen M, Rammensee HG, Sahin U, Hinz T, Kalinke U.

Nat Biotechnol. 2013 Oct;31(10):880-2. doi: 10.1038/nbt.2708. No abstract available.

PMID:
24104749
4.

[Trends in vaccine development].

Scherer J, Hinz T, Cichutek K.

Pharm Unserer Zeit. 2008;37(1):86-92. Review. German. No abstract available.

PMID:
18081053
5.

Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective.

Hinz T, Buchholz CJ, van der Stappen T, Cichutek K, Kalinke U.

J Immunother. 2006 Sep-Oct;29(5):472-6. Review.

PMID:
16971803

Supplemental Content

Loading ...
Support Center